Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
Lead PI: Professor Mark Parsons
No. of Patients Currently Recruited: 453 No. of Patients Required: 728
Multicentre, prospective, randomised open-label blinded endpoint (PROBE) phase III study including acute stroke patients with hemispheric ischaemia who have penumbra on perfusion CT (CTP) or MRI within 4.5 hours of stroke onset. The primary objective of this study is to test the hypothesis that patients with acute hemispheric ischaemic stroke who have a penumbra on perfusion CT or MRI within 4.5hrs of symptom onset will have less disability at 3 months when treated with IV TNK compared to IV tPA.